References
- Tam CS, O'Brien S, Wierda W, et al Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112:975–980.
- Dohner H, Stilgenbauer S, Benner A, et al Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910–1916.
- Austen B, Powell J, Alvi A, et al Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. Blood 2005;106:3175–3182.
- Kotla V, Goel S, Nischal S, et al Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2009;2:36.
- Chanan-Khan A, Miller K, Musial L, et al Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006;24:5343–5349.
- Sher T, Miller K, Lawrence D, et al Efficacy of lenalidomide in chronic lymphocytic leukemia patients with high-risk cytogenetics. Leuk Lymphoma 2010;51:85–88.
- Ferrajoli A, Lee BN, Schlette EJ, et al Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111:5291–5297.
- Lozanski G, Heerema NA, Flinn IW, et al Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004;103:3278–3281.
- Thornton PD, Matutes E, Bosanquet AG, et al High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Ann Hematol 2003;82:759–765.
- Fischer K, Stilgenbauer S, Schweighofer CD, et al Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre phase II trial of the German CLL Study Group (GCLLSG). Blood 2008;112:128.
- Lin TS, Heerema NA, Lozanski G, et al Flavopiridol (Alvocidib) induces durable responses in relapsed chronic lymphocytic leukemia (CLL) patients with high-risk cytogenetic abnormalities. Blood 2008;112:23–24.